Bausch + Lomb Overview
- Founded
-
1853
- Status
-
Public
- Employees
-
12,800
- Stock Symbol
-
BLCO
- Investments
-
27
- Share Price
-
$17.45
- (As of Friday Closing)
Bausch + Lomb General Information
Description
Bausch & Lomb, headquartered in Laval, Quebec, Canada, is the fourth-largest vision care company by sales in the United States and the market leader in consumer vision care in India and China. The firm, which was previously a subsidiary under parent company Bausch Health, was spun off to become a public company once again in May 2022. The firm reports in three segments-vision care and consumer (60% of revenue), surgical (20%), and ophthalmic pharmaceuticals (20%). The company is geographically diversified, with 48% of revenue in the Americas, 30% from EMEA, and 22% from Asia-Pacific countries.
Contact Information
Primary Industry
Therapeutic Devices
Other Industries
Surgical Devices
Pharmaceuticals
Stock Exchange
TSE
Primary Office
- 400 Somerset Corporate Boulevard
- Bridgewater, NJ 08807
- United States
+1 (800) 000-0000
Bausch + Lomb Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $17.45 | $17.60 | $12.44 - $20.07 | $6.11B | 350M | 4.32K | $0.17 |
Bausch + Lomb Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 7,523,557 | |||
| Revenue | 3,773,000 | 3,765,000 | 3,412,000 | 3,778,000 |
| EBITDA | 643,000 | 733,000 | 729,000 | 867,000 |
| Net Income | 58,000 | 182,000 | (18,000) | 298,000 |
| Total Assets | 10,696,000 | 10,823,000 | 11,266,000 | 11,468,000 |
| Total Debt | 2,438,000 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Bausch + Lomb Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bausch + Lomb Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Bausch & Lomb, headquartered in Laval, Quebec, Canada, is the fourth-largest vision care company by sales in the United
Therapeutic Devices
Bridgewater, NJ
12,800
As of 2022
00000
0.00
0000-00-00
00000000
00000
000000
o eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim v
00000000000 0000000
Aliso Viejo, CA
000
As of 0000
00000
0000
0000-00-00
00000000
00000
000000
mmodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
00000000000 0000000
Charenton-le-Pont, France
000000
As of 0000
000000000
Add Comparison
Bausch + Lomb Competitors (6)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| RxSight | Formerly VC-backed | Aliso Viejo, CA | 000 | 00000 | 00000000 | 00000 |
| 0000000 | Corporation | Charenton-le-Pont, France | 000000 | 000000000 | ||
| 0000000000 | Formerly VC-backed | Carlsbad, CA | 00 | 000.00 | 000000&0 | 000.00 |
| 000000 | Formerly VC-backed | Mountain View, CA | 000 | 000.00 | 000000000 - | 000.00 |
| 00000000 | Formerly VC-backed | Irvine, CA | 00 | 0000 | 000000&0 | 0000 |
Bausch + Lomb Patents
Bausch + Lomb Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200375681-A1 | Detachable finger-activated surgical control device | Inactive | 03-Jun-2019 | 000000000 | |
| CA-3132335-A1 | Glycophospholipid polymeric network and use thereof | Pending | 29-Apr-2019 | 00000000000 | |
| EP-3962961-A1 | Glycophospholipid polymeric network and use thereof | Pending | 29-Apr-2019 | 00000000000 | |
| JP-2022530253-A | Glycophospholipid polymer network and its use | Pending | 29-Apr-2019 | 00000000000 | |
| US-20200339710-A1 | Glycophospholipid polymeric network and use thereof | Pending | 29-Apr-2019 | C08B37/0063 | 0 |
Bausch + Lomb Executive Team (34)
Bausch + Lomb Board Members (16)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 000 0000000 | Self | Board Member | 000 0000 |
| 00000 00000 | Bausch + Lomb | Board Member | 000 0000 |
| 00000 00000 | Self | Board Member | 000 0000 |
| 0000 00 | Self | Board Member | 000 0000 |
| 0000 0000000 | Self | Board Member | 000 0000 |
Bausch + Lomb Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Bausch + Lomb Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bausch + Lomb Investments & Acquisitions (27)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 00000000 | 17-Jan-2023 | 0000000000 | Therapeutic Devices | 000000 00 | |
| 000000000 | 27-Jul-2022 | 00000 0000 | 0000 | Surgical Devices | 000000 00 |
| 00000 0000000 | 12-Jan-2016 | 0000000000 | Therapeutic Devices | 0000 0000 | |
| 000000'0 0000 | 23-Oct-2015 | 0000000000 | Diagnostic Equipment | 00000 000 | |
| Innovative Sclerals | 24-Apr-2015 | Merger/Acquisition | Therapeutic Devices | 000 00000 |
Bausch + Lomb Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 00000000000 00ö000 | Accessories | Buenos Aires, Argentina | 0000 |
Bausch + Lomb Exits (3)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 0000000 0000 00000 | 01-Jan-2000 | 000000000000000000 | Completed |
|
|
| 0000000-000 | 01-Jan-1993 | 000000000000000000 | Completed |
|
|
| Minnesota Eye Consultants | Corporate | Completed |